Navigation Links
Response Genetics Reports Second Quarter 2007 Financial Results
Date:8/19/2007

rter of the prior year. The increases in cost of revenue, research and development, and general and administrative expenses were primarily due to 1) stock option grants to employees at the time of the Company's initial public offering totaling $1.0 million, 2) Operating costs related to the set- up and continuing operation of the European laboratory totaling $570,000, and 3) costs associated with an hiring personnel to support the company's growth, costs involving the new testing services the Company is offering, maintaining the Company's patent position, and costs related the completion of the Company's IPO and costs associated with being a public company totaling $880,000. Total operating expenses for the second quarter of 2007 increased to $4.0 million, compared with $1.5 million for the same period last year.

Response Genetics' net loss for the second quarter of 2007 of $2.5 million, or $0.58 per share, compared with $746,962, or $0.36 per share, for the second quarter of 2006.

Financial Results for Six Months Ended June 30, 2007

Revenues for the first six months of 2007 increased to $3.1 million, compared with $2.0 million for the first six months of 2006. Cost of revenue for the first six months of 2007 was $2.0 million, compared with $978,130 reported for the first six months of 2006. General and administrative expenses for the first six months of the year were $3.2 million, compared to $1.6 million for the comparable period in 2006. Research and development expenses in the first half of 2007 totaled $1.2 million, compared to $595,702 for the comparable period in 2006. Total operating expenses for the first six months of 2007 were $6.4 million, versus $3.2 million for the comparable period in 2006. Response Genetics reported a net loss for the six months ended June 30, 2007 of $3.2 million, or $1.00 per share, versus a net loss for the comparable period in 2006 of $920,552, or $0.51 per share.

Cash and Cash Equivalents

Cash and c
'/>"/>

SOURCE Response Genetics, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Performance of Ad-A-Gene Cyclic AMP Response Element-Nitroreductase (CRE-NTR): an adenoviral vector gene delivery system
2. FLIPR Calcium 3 Assay Kit - An Optimal No-Wash Fluorescence Calcium Indicator Reagent for Non-Optimal Calcium Responses
3. IT critical in pandemic response, but many are not paying attention
4. Quick response manufacturing and biotech
5. Wisconsin court affirms damages in Innogenetics, Abbott patent case
6. Third Wave licenses Innogenetics tech to settle lawsuit
7. Symposium examines the effect of race on genetics and disease
8. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
9. Sonic Foundry reports GAAP loss as Q2 revenues rise
10. Fiserv reports $113.5 million in Q1 profit
11. Third Wave reports net loss of $18.9M for 2006
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... The Activated Carbon Manufacturing industry ... IBISWorld updated its original industry research report. , ... intensified focus on environmental policy. Over the five years ... power plants and a range of other industrial facilities ... Sarah Kahn, “a range of downstream industrial sectors rely ...
(Date:12/17/2014)... RIDGE, N.J. (PRWEB) December 17, 2014 ... (Euronext: IPN; ADR: IPSEY), today ... mg (referred to as Somatuline®) was approved by ... the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in ... locally advanced or metastatic disease to improve progression-free ...
(Date:12/17/2014)... December 17, 2014 Gene synthesis ... it has entered into a technology access and ... to apply DNA2.0’s proprietary protein engineering technology, known ... , “We are extremely excited that the global ... This proprietary bioengineering technology has now been ...
(Date:12/17/2014)... CASI Pharmaceuticals, Inc. (Nasdaq: CASI ... and commercialization of innovative therapeutics addressing cancer and other ... primary commercial focus on China , ... C meeting with the U.S. Food and Drug Administration ... February 2015.  During this meeting the Company will seek ...
Breaking Biology Technology:Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 2Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5
... DENVER, Colorado and JERUSALEM, September 16 Children,s,Hospital ... today,that Children,s Hospital is enrolling patients for the ExCell ... cord blood transplant sites,worldwide, five of which are children,s ... Hungary and Israel. The trial is researching the,safety and ...
... , ... Highly Automated QT(sm) and QT Beat-to-Beat(sm) to Improve Precision and Reduce Risk of False ... Rochester, ... core lab services and QT analysis, announced today that a top 15 pharmaceutical company ...
... , , , ST. LOUIS, ... be presenting at the UBS Global Life Sciences Conference on Monday, ... NY. Interested parties may listen via live audio broadcast over the ... the "Webcast" icon to access this file. , , ...
Cached Biology Technology:Children's Hospital in Colorado Rounds off List of 24 Cord Blood Transplant Centers Worldwide Enrolling for ExCell Trial Studying StemEx(R) for Leukemia and Lymphoma 2Children's Hospital in Colorado Rounds off List of 24 Cord Blood Transplant Centers Worldwide Enrolling for ExCell Trial Studying StemEx(R) for Leukemia and Lymphoma 3Children's Hospital in Colorado Rounds off List of 24 Cord Blood Transplant Centers Worldwide Enrolling for ExCell Trial Studying StemEx(R) for Leukemia and Lymphoma 4Top 15 Pharmaceutical Company Awards Cardiac Safety Study to iCardiac 2
(Date:12/3/2014)... Ariz. , Dec. 2, 2014 As ... hand readers, Inception Technologies is pleased to announce the ... easier for customers to collect the workforce data that ... problems that have been left by existing readers. Many ... user interface, connectivity and modern technology. Older models force ...
(Date:11/21/2014)... , Nov. 20, 2014 C-Labs LLC, ... the Internet of Things (IoT), today announced the appointment ... chief operating officer. Previously a strategic advisor to the ... and operations. Mr. Traynor is based out of the ... He reports to Chris Muench , Chief Executive ...
(Date:11/18/2014)... 17, 2014 The Parenteral Drug Association (PDA) today ... will speak and at least seven more will participate in ... Omni Shoreham Hotel in Washington D.C. , ... have significant support from the regulatory agencies in ... in our effort to help advance the use of ...
Breaking Biology News(10 mins):Inception Technologies to Release New Biometric Reader 2C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2
... University researchers is examining a new vaccine method that ... Wannemuehler and his team of researchers is hoping to ... use smaller doses and require only one trip to ... been prepared from killed bacteria. The vaccinated person,s immune ...
... available in French . A ... McGill Universitys Department of Microbiology and Immunology has discovered ... regulate the bodys autoimmune reactions may lose their effectiveness ... of type 1 diabetes. The study conducted on ...
... 2008 The Rwandan government, Great Ape Trust of ... Reserve is the future site of the Rwanda National ... ambitious forest restoration and ecological research efforts ever. The ... national conservation park comes less than three months after ...
Cached Biology News:Iowa State researchers look for smaller, cheaper, 1-dose vaccines 2Type 1 diabetes triggered by 'lazy' regulatory T-cells: McGill researchers 2Rwanda's Gishwati Forest selected as site for historic conservation project 2Rwanda's Gishwati Forest selected as site for historic conservation project 3
... designed for genome-wide microRNA expression profiling ... powerful Paraflo microfluidic on-chip synthesis platform. ... of our comprehensive microRNA Expression Profiling ... The Arabidopsis microRNA Microarray contains all ...
... MIDAS TRAQ systems integrate the unique ... Q TRAP and 3200 Q TRAP LC/MS/MS ... System plus automation software, to provide a ... protein biomarkers. , , Eliminate extensive ...
... and compact GC-8A is Shimadzu's basic gas ... simple to use, the GC-8A supports a ... on column injection port(s), and analog output. ... are available. The GC-8A is only 17.3 ...
... The PolarScreen Peroxisome Proliferator-Activated Receptor-gamma ... a sensitive and efficient method ... PPARGamma ligands using fluorescence polarization ... PPARGamma-Ligand binding domain (PPARGamma-LBD) with ...
Biology Products: